Table of Content

1. Introduction to Bcr-Abl Inhibitors
1.1 Overview
1.2 Evolution of Bcr-Abl Inhibitors


2. Bcr-Abl Inhibitor - Mechanism of Action
2.1 Overview
2.2 Role of Bcr-Abl Inhibitor in Cancer


3. Global Bcr-Abl Inhibitor Drug Market Insight
3.1 Current Market Scenario
3.2 Future Market Opportunity


4. Bcr-Abl Inhibitor Drug Market Regional Analysis
4.1 US
4.2 Europe
4.3 Japan
4.4 Rest of World


5. Bcr-Abl Inhibitor Drug Market by Product
5.1 First Generation Bcr-Abl Inhibitor
5.2 Second Generation Bcr-Abl Inhibitor
5.3 Third Generation Bcr-Abl Inhibitor


6. Imatinib – 1st Generation Bcr-Abl Inhibitor 2001
6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis


7. Dasatinib – 2nd Generation Bcr-Abl Inhibitor 2006
7.1 Overview
7.2 Patent & Exclusivity
7.3 Pricing & Dosage Analysis
7.3.1 Branded
7.3.2 Generic
7.4 Sales Analysis


8. Nilotinib – 2nd Generation Bcr-Abl Inhibitor 2007
8.1 Overview
8.2 Patent & Exclusivity
8.3 Price & Dosage Analysis
8.4 Sales Analysis


9. Bosutinib – 2nd Generation Bcr-Abl Inhibitor 2012
9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis


10. Ponatinib – 3rd Generation Bcr-Abl Inhibitor 2012
10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis


11. Asciminib – 3rd Generation Bcr-Abl Inhibitor 2021
11.1 Overview
11.2 Patent & Exclusivity
11.3 Pricing & Dosage Analysis


12. Olverembatinib – 3rd Generation Bcr-Abl Inhibitor 2021


13. Bcr-Abl Inhibitors Sales Forecast 2022 Till 2028
13.1 Gleevec/Glivec Sales Forecast
13.2 Sprycel Sales Forecast
13.3 Tasigna Sales Forecast
13.4 Bosulif Sales Forecast
13.5 Iclusig Sales Forecast


14. Bcr-Abl Inhibitor Market Clinical Trial Insights
14.1 By Indication
14.2 By Organization
14.3 By Patient Segment
14.4 By Phase
14.5 By Status
14.6 By Region


15. Global Bcr-Abl Tyrosine Kinase Inhibitors Clinical Trials Insight By Company, Indication & Phase
15.1 Preclinical
15.2 Clinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-II/III
15.7 Registered


16. Marketed Bcr-Abl Inhibitors Clinical Trials Insight


17. Bcr-Abl Inhibitors Market Dynamics
17.1 Market Favorable Parameters
17.2 Market Challenges


18. Bcr-Abl Inhibitor Market Future Perspective


19. Competitive Landscape
19.1 Ascentage Pharma
19.2 AstraZeneca
19.3 Bristol Myers Squibb
19.4 Fusion Pharmaceuticals
19.5 Incyte Pharmaceutical
19.6 Merck
19.7 Novartis
19.8 Pfizer
19.9 Takeda Pharmaceuticals
19.10 Teva Pharmaceutical